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Interactome Mapping Uncovers a General Role
for Numb in Protein Kinase Regulation*□
S

Ran Wei‡, Tomonori Kaneko‡, Xuguang Liu‡, Huadong Liu‡§, Lei Li‡¶储,
Courtney Voss‡, Eric Liu‡, Ningning He¶储, and Shawn S.-C. Li‡**‡‡
Cellular functions are frequently regulated by protein-protein interactions involving the binding of a modular domain in one protein to a specific peptide sequence in
another. This mechanism may be explored to identify
binding partners for proteins harboring a peptide-recognition domain. Here we report a proteomic strategy combining peptide and protein microarray screening with
biochemical and cellular assays to identify modular domain-mediated protein-protein interactions in a systematic manner. We applied this strategy to Numb, a multifunctional protein containing a phosphotyrosine-binding
(PTB) domain. Through the screening of a protein microarray, we identified >100 protein kinases, including
both Tyr and Ser/Thr kinases, that could potentially interact with the Numb PTB domain, suggesting a general role
for Numb in regulating kinase function. The putative interactions between Numb and several tyrosine kinases
were subsequently validated by GST pull-down and/or
co-immunoprecipitation assays. Furthermore, using the
Oriented Peptide Array Library approach, we defined the
specificity of the Numb PTB domain which, in turn, allowed us to predict binding partners for Numb at the
genome level. The combination of the protein microarray
screening with computer-aided prediction produced the
most expansive interactome for Numb to date, implicating
Numb in regulating phosphorylation signaling through
protein kinases and phosphatases. Not only does the data
generated from this study provide an important resource
for hypothesis-driven research to further define the function of Numb, the proteomic strategy described herein
may be employed to uncover the interactome for other
peptide-recognition domains whose consensus motifs
are known or can be determined. Molecular & Cellular
Proteomics 17: 10.1074/mcp.RA117.000114, 2216–2228,
2018.

Protein-protein interactions (PPIs)1 play a pivotal role in all
essential cellular processes, and dysregulation of PPI may

lead to diseases such as cancer (1). Identification and characterization of the binding partners for a protein is crucial for
the systematic understanding of its function. This study is
focused on identifying and characterizing the interactome of
Numb, originally identified for its role in asymmetric cell division (2– 4). At the molecular level, Numb exhibits a complex
array of functions and is involved in a multitude of biological
processes including ubiquitination-mediated protein degradation, endocytosis, cell adhesion, cell polarity, cell migration
and tumorigenesis (5). This wide range of roles is likely because of the ability of Numb to bind to a variety of different
proteins. Accordingly, most Numb functions were uncovered
through the identification of novel Numb-binding proteins. For
instance, Numb was found to play a role in protein ubiquitination by directly interacting with the E3 ligase Mdm2 (6),
Lnx1 (7), Itch (8) or Siah1 (9). Numb has also been identified as
an endocytic protein as it interacts with the endocytosis regulators EH, EPS15, EPS15R and AP-2 (10, 11) and localizes to
the cytoplasmic membrane (12). During endocytosis, Numb
mediates the internalization of a number of membrane-associated proteins, including Notch, Integrins, E-cadherin and
TrkB, all of which were identified through their interactions
with Numb (13–17). Similarly, the function of Numb in cell
polarity and migration was discovered along with the identification of Numb-Par complex (Par3/Par6/aPKC) interaction
(14 –16).
As an adaptor protein, Numb contains a prototypical protein-protein interaction domain, the phosphotyrosine binding
(PTB) domain that is evolutionarily and functionally conserved.
Based on the SMART database (18, 19), there exist at least
5208 PTB domains from 4530 proteins across different species. The human genome encodes 46 proteins harboring 51
PTB domains. PTB domain-containing proteins are often
adaptors and scaffold proteins, which organize and regulate
the signaling networks involved in a wide variety of biological
processes (20). PTB domains can be divided into three
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groups: IRS-1/Dok-like, Shc-like, and Dab-like (20). The IRS1/Dok-like and Shc-like groups bind to their ligands in a
phosphotyrosine-dependent manner. The Dab-like group also
recognizes tyrosine residues, but the binding is phosphorylation independent. Numb PTB is one of many PTB domains
that belong to the latter group. Even though they are not
directly involved in tyrosine phosphorylation mediated signaling transduction, Dab-like PTB containing proteins participate
in the regulation of various cellular events such as endocytosis (21, 22), membrane protein processing (23, 24), asymmetric cell division (25) and integrin-mediated cell adhesion
(26, 27).
Considering the long and continually growing list of proteins
that interact with Numb, it is not surprising that Numb has
been implicated in cancer as a tumor suppressor. The role of
Numb in cancer is mediated, in part, by it interactions with the
Notch receptor and the Mdm2/p53 complex. Numb directly
binds to Notch (28) and p53 (29) through its PTB domain but
regulates Notch and p53 via different mechanisms. Numb
promotes the internalization and subsequent degradation of
cell membrane-localized Notch, thus attenuating Notch signaling in cell proliferation (13, 30). In contrast, Numb stabilizes
p53 by preventing Mdm2-mediated ubiquitination and degradation of p53 (31). Both the Numb-Notch and Numb-p53
interactions bear great potential for the development of novel
anti-cancer targeted therapeutics. It is conceivable that a
systematic investigation of the Numb interactome would facilitate the exploration of Numb as a therapeutic target. In this
regard, several high-throughput methods have been developed for interactome mapping. These include the affinity purification-mass spectrometry (AP-MS), the yeast two-hybrid
(Y2H) (32), and the luminescence-based mammalian interactome mapping (LUMIER) (33) approaches.
We have developed an integrated peptide/protein array
strategy to map the interactome of Numb, focusing on its PTB
domain. Combining protein microarray screening with domain
specificity-based prediction, we identified the most expansive
interactome for Numb reported to date. Intriguingly, the Numb
interactome is characterized with a large number of protein
kinases and phosphatases. Our work has greatly expanded
the current knowledge of the Numb interactome and suggests
a broad role for Numb in regulating cellular functions mediated by protein phosphorylation.
MATERIALS AND METHODS

Reagents and Antibodies—The SKBR3, Hela and HCC78 cell lines
were obtained from American Tissue Culture Collection. The H2228
cell line was a gift from Dr. Pasi A. Janne (Dana-Farber Cancer
Institute, Boston, MA). The SH-SY5Y cell line was a gift from Dr. Jane
R. Rylett (Western University, London, ON). The SKBR3 and HCC78
cells were cultured in RPMI 1640 medium (Sigma, MO, Cat. No.
R8758). The Hela and SH-SY5Y cells were cultured in Dulbecco’s
1

The abbreviations used are: PPI, protein-protein interactions; SH,
Src homology.
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Modified Eagle Medium (Sigma) supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100 g/ml Streptomycin. Reagents
used included Alexa Fluor 647 streptavidin (Thermo Fisher scientific,
MA, Cat. No. S21374), rabbit polyclonal anti-Numb (H-70) (Santa
Cruz, Cat. No. sc-25668), rabbit monoclonal anti-ALK (Cell signaling,
MA, Cat. No. 3633), mouse monoclonal anti-ErbB2 (Thermo Fisher
scientific, Cat. No. MA5-13105), rabbit monoclonal anti-ROS1(Cell
signaling, Cat. No. 3287), rabbit monoclonal anti-Ret (Cell signaling,
Cat. No. 14556), rabbit polyclonal anti-FGR (N-47) (Santa Cruz, Cat.
No. sc-130), rabbit monoclonal anti-Flt3 (Cell signaling, Cat. No.
3462).
GST-Numb-PTB Protein Expression, Purification, and Biotinylation—The BL21 strain of E. coli was transformed with the pGEX6P3dNumb-PTB, pGEX6P3-hNumb-PTB plasmids (29, 34). Positive colonies were cultured in Lysogeny Broth (LB) medium to a density of
OD600 0.6⬃0.8, then the protein expression was induced with 0.5 mM
IPTG for 16 h at 18 °C. The bacterial cells were harvested and pellets
were resuspended in PBS buffer containing a mixture of protease
inhibitors (Roche, Cat. No. 04693116001). Triton X-100 was added to
a final concentration of 2%, lysozyme at 1 mg/ml and benzonase at
20 units/ml. The suspension was lysed on ice for 30 min. Lysates were
centrifuged at 15,000 ⫻ g for 30 min at 4 °C and the supernatant was
collected. Purification of GST-fused proteins was performed with
glutathione Sepharose resin (GE Healthcare Life Sciences, MA, Cat.
No. 17075601). The Sepharose was first washed with 10 bed volumes
of PBS buffer. The lysate supernatant was then loaded to the resin
followed by three column volume washes with PBS buffer, then eluted
with 10 mM glutathione in Tris buffer (50 mM Tris-HCl, pH 8.0, 100 mM
NaCl) (no elution step for pulldown assays). To determine GST-protein purity, a small amount of the purified protein (or protein on resin)
was boiled in SDS-sample buffer and then analyzed by SDS-PAGE
followed by Coomassie staining. The GST Numb PTB domains used
for the ProtoArray hybridization was biotin-labeled, purified and quantified using the ProtoArray Mini-Biotinylation Kit (Invitrogen, CA, Cat.
No. AL-01). The level of protein biotinylation is assessed by comparing the Western blotting signals from streptavidin-HRP between biotinylated GST Numb PTB domains and the biotinylated Gel Standard
provided by the Kit.
ProtoArray Hybridization—The ProtoArray (Human protein microarray v4.0, Invitrogen, Cat. No. PAH0524011) was removed from
⫺20 °C and placed immediately at 4 °C for at least 15 min. The array
was arranged barcode-side up in each well of a pre-chilled 4-chamber incubation tray. PBST Blocking buffer (1⫻ PBS, 1% BSA, 0.1%
Tween 20) was then added and the buffer immersed microarray slide
was incubated for 1 h at 4 °C with gentle rocking. The blocking buffer
was then removed and the slide drained. Biotinylated protein probes
(120 l at 50 g/ml) in probing buffer (1⫻ PBS, 5 mM MgCl2, 0.5 mM
DTT, 0.05% Triton X-100, 5% Glycerol, 1% BSA) was added on top
of the microarray surface and a cover glass was carefully placed on
the array. The array was blotted for 90 min at 4 °C without shaking.
The cover glass was then removed, and the array was washed
with the probing buffer 3 times each for 5 min at 4 °C. The array was
visualized by incubating with 5 ml Alexa Fluor 647-conjugated
streptavidin at a dilution 1:3000 in the probing buffer for 30 min at
4 °C in the dark. Then the array was washed again following the same
procedures as above. Finally, the array was dipped into distilled water
once to remove salt residues and kept in dark to air dry. The array was
scanned on a microarray laser scanner (Tecan Co., Morrisville, NC).
Data were analyzed using the Array-Pro analyzer software (Tecan,
Co.). Z-score was calculated using the formula: (measured value ⫺
average value)/standard deviation. The signals corresponding to the
positive and negative control dots were excluded from the Z-score
calculation (see also supplemental Table S2 and S3; the Z-scores are
under the column “Signal Used”).
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Peptide and Peptide Array Synthesis—Both free and membranebound peptides (spot arrays) were synthesized on an automatic Intavis AG peptide synthesizer using Fmoc (9-fluorenylmethyl-oxycarbonyl) chemistry. Rink-resin (Rink-NH2) was used to couple the first
amino acid in free peptide synthesis, whereas the amine-derivative
cellulose membrane (cellulose-NH2) was made to couple the first
amino acid by on-membrane peptide synthesis. In each synthesis
cycle, the carboxyl group of a Fmoc-protected amino acid (FmocAA-COOH) was first linked to the amine group of the previous amino
acid (or Rink-NH2) through an amide bond. All unoccupied amine
groups were then blocked (acetylated) by acetic anhydride to prevent
incorrect amide bond formation in subsequent cycles. Next, the Fmoc
group was removed by piperidine (de-protection) to release the free
amine group for coupling to the carboxyl group of the next amino acid
residue. Fluorescein-NHS was added at the last coupling cycle to
label to the peptide in free peptide synthesis. On completion of
synthesis, the peptide spot membrane was treated with a mixture
containing 47.5% TFA (trifluoroacetic acid), 1.5% TIPS (tri-isopropylsilane) and 51% H2O, to remove all remaining side-chain protecting
groups. Alternatively, the free peptide-resin was incubated in a mixture containing 95% TFA, 3% TIPS and 2% H2O to deprotect side
chains and cleave the peptide from Rink-resin simultaneously.
Far-Western Blotting of Peptide Array—The peptide spot array
membrane was blocked with 3% BSA in TBST buffer (0.1 M Tris-HCl,
pH 7.4, 150 mM NaCl, and 0.1% Tween 20) for 1 h at room temperature, with gentle rocking. GST-fusion proteins were added directly
into the blocking buffer to reach a final concentration of 1 g/ml and
incubated with the peptide array membrane for 1 h at room temperature, with gentle shaking. The membrane was then washed in TBST
buffer three times for 5 min each with shaking. Next, anti-GST-HRP
antibody was added at 1:5000 (v/v) into 3% BSA in TBST buffer. The
membrane was incubated for 1 h at room temperature with shaking
followed by the same washing procedures as above. Finally, the
bound GST-protein signal was visualized using ECL and quantified by
the Array-Pro analyzer software. The Z-score of a peptide spot was
calculated the same way as for a protein dot on the ProtoArray.
Dissociation Constant Determination—The dissociation constant of
a PTB-peptide interaction was determined by fluorescence polarization (FP) using fluorescein-labeled peptide (a linker, 6-aminohexanoic
acid, was inserted between fluorescein and the first amino acid of the
peptide). All binding assays were carried out in Tris Buffer (50 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM DTT) and at least two independent experiments were performed for each peptide. The FP assays were carried out in 384-well flat bottom plates (Corning-3537)
and the fluorescence polarization signals detected on an Envision
Multilabel Plate Reader (PerkinElmer, Waltham, MA) with excitation
set at 480 nM and emission at 535 nm. Binding curves were derived
from fitting the isothermal titration data to a hyperbolic nonlinear
regression model using Prism 3.0 (GraphPad software, Inc., San
Diego, CA). The corresponding dissociation constants (Kd) was also
calculated by Prism 3.0.
Immunoprecipitation, GST Pulldown and Western Blotting—Cultured cells were lysed in ice-cold lysis buffer (1% Triton X-100, 50 mM
Tris-pH 7.2, 150 mM NaCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA,
0.5 mM DTT, 10 mM NaF) containing complete protease inhibitors
(Roche, Basel, Switzerland). Cell debris was removed by centrifugation, and 500 g of supernatant protein was incubated for four hours
in the presence of 1 g antibody and 30 l of 50% slurry protein G
Resin (GenScript, NJ, Cat. No. L00209), or 10 g immobilized GST
fusion protein. The beads were subsequently washed three times with
lysis buffer and boiled with SDS-loading dye. The precipitates were
resolved by SDS-PAGE. Proteins were then transferred to polyvinylidene fluoride PVDF membrane using semi-dry transferring
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FIG. 1. Systematic identification of Numb-binding proteins. A
workflow highlighting the strategy used in this study to identify proteins that bind specifically to the Numb PTB domain.
method and detected by immunoblotting with appropriate antibodies
and visualized by enhanced chemi-luminescence (ECL).
Consensus Binding Motif and Scoring Matrix—OPAL membranes
were prepared as previous described (35). Upon binding to the PTB
domain, the OPAL membrane was scanned, and the spot intensity
quantified on a Bio-Rad imaging system. To generate consensus
motifs based on the specific binding signals, the average background
signal of the membrane was subtracted from the spot signal. To
minimize position-independent effect, the value for each Lys or Arg
spot was readjusted by subtracting the average of the Lys or Arg in
the column. A scoring matrix was derived from the average, normalized signals for each position of the peptide on two OPAL membranes
(36). The scoring matrix was then imported to SMALI and used to
search the UniProt protein database (37) to generate a ranked list of
potential Numb PTB domain binding peptides/proteins.
RESULTS

Identification of Modular Domain-binding Proteins by Complementary Peptide and Protein Array Screening—We have
developed an integrative approach combining protein and
peptide array screening with computer-aided ligand prediction to systematically identify the PPI network mediated by
modular domains. We evaluated this approach using the
Numb PTB domain. As shown in Fig. 1, our workflow started
with probing a protein microarray by the purified PTB domain
to produce the first interactome. Based on the sequence motif
Nxx[F/Y] (where x represents any amino acid residue) recognized by the PTB domain (38, 39), we then scanned this
interactome for proteins containing this motif and synthesized
the corresponding peptides on a nitrocellulose membrane.

Molecular & Cellular Proteomics 17.11
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FIG. 2. A Numb PTB interactome identified by screening a protein microarray. A, B, Representative sections of a protein microarray
(ProtoArray, Invitrogen) probed with the dNumb PTB domain. Protein spots that showed positive binding (red dots) were labeled. Control 1
spots represent Alexa Fluor 647 Rabbit anti-mouse IgG antibody; Control 2 spots represent Biotinylated anti-mouse antibody. C, A Venn
diagram illustrating all potential binders of the dNumb or hNumb PTB domains identified from screening the ProtoArray and their overlap. D–F,
Venn diagrams showing the protein kinases that bound the dNumb or/and the hNumb PTB domain.

The resulting peptide spot array was then probed by the
Numb PTB, and the positive hits were subsequently validated
by in-solution binding assays. Finally, interactions corresponding to high affinity (i.e. dissociation constant Kd ⬍ 10
M) domain-peptide binding were validated by GST-pulldown
or co-immunoprecipitation (IP) using cells expressing the fulllength target proteins. In complement to the protein microarray screening, Oriented Peptide Array Library (OPAL) (35) was
employed to further define the specificity of the Numb PTB
domain and the resulting specificity-profile was used to predict binding proteins at the genome level by the computer
program SMALI (36).
Identification of Numb Binding Proteins by Screening a
Protein Microarray—To identify binders of the Numb PTB
domain in an unbiased manner, we took advantage of a
protein microarray (ProtoArray, Invitrogen) that contained
8,274 human proteins (with each protein printed in duplicate;
supplemental Fig. S1 and supplemental Table S1). Specifically, the ProtoArray microarray slide was probed with 5 M of
biotinylated, GST-tagged Drosophila Numb-PTB (dPTB) or

Molecular & Cellular Proteomics 17.11

human Numb PTB (hPTB, the isoform lacking the PTB insert
(12)) domain. Although the ProtoArray contained only human
proteins, we included both the dPTB and hPTB domains in the
screen and subsequent binding studies because the two PTB
homologues are similar in specificity and the recombinant
dPTB protein is more stable than the hPTB (38, 39). The
bound proteins were identified by streptavidin labeled with
Alexa Fluor 647. The fluorescent signal was recorded on a
microarray laser scanner (Fig. 2A and 2B and supplemental
Fig. S2 and 3) and analyzed using the ArrayProxy software
(supplemental Figs. S2 and S3, supplemental Table S2
and S3).
Because the duplicate spots of certain proteins on the
ProtoArray showed large variations in binding signal (due
likely to printing defects), we included in the analysis only
proteins for which the average signal over standard deviation
is greater than 7.5 or Avg/Std ⬎7.5. A Z-score was then
calculated for each protein based on the corresponding Avg
value. A protein was considered a positive binder when the
Z ⱖ 2.0 (supplemental Figs. S2 and S3). Using these criteria,

2219

Characterization of Numb Interactome

we identified 285 candidate binding proteins for dPTB and
251 for hPTB (supplemental Tables S4 and S5) of which 128
were common to both domains (Fig. 2C). Intriguingly, 145/408
(⬎35%) of the identified PTB-binders were protein kinases
(Fig. 2C and 2D). This number increased to ⬎40% when the
identified interactome for dPTB and hPTB was analyzed separately (supplemental Figs. S2 and S3). Of the 87 kinases
bound to both PTB domains, 46 were Ser/Thr kinase (STK)
and 42 are tyrosine kinases (TK) (Fig. 2E and 2F). Except for
PRKCQ, PRKCG, PRKCE, PRKCB, PRKCA and CAMK2B
that have been reported as Numb-interacting proteins (40 –
42), the remaining kinases are new. That the PTB-binding
kinases occupy essentially all branches of the human kinome phylogenetic tree (supplemental Fig. S4) suggests
that Numb may play a general role in regulating protein
kinase function.
Characterization of PTB-binding Motifs in the Numb Interactome Identified from the ProtoArray Screening—The Numb
PTB domain is capable of binding to proteins containing the
Nxx[Y/F] motif (38, 39). To identify high affinity-binders from
the ProtoArray screen, we searched for the presence of this
motif in proteins on the ProtoArray that produced a Z-score
ⱖ2.0 when probed with both the dPTB and hPTB domains.
This led to the identification of 260 Nxx[Y/F]-containing sequences from 94 proteins. The corresponding peptides were
synthesized on a nitrocellulose membrane as a spot array
(supplemental Fig. S5A and supplemental Table S8). The
PTB-binding peptides GLDNPAYVS from human LNX1 and
GFSNMSFED from Drosophila NAK (38) were included as
positive controls. The LNX1 and NAK peptides containing
the N-to-A substitution (39), and the human TrkA peptide
(IIENPQYFS) (43) were used as negative controls (supplemental Table S8). The peptide spot array was probed for binding
to the purified Numb PTB domain. Because the dNumb PTB
domain was more stable than the mammalian counterpart
(39), we employed the GST-dPTB protein to probe the peptide
array as well as in subsequent binding assays carried out in
solution. An anti-GST Far-Western blotting revealed that ⬎
40% peptides on the spot array exhibited binding to the
dPTB protein, albeit with large variance in the binding signal
(Fig. 3A).
Intriguingly, only 19 peptides (excluding the controls) on the
spot array yielded signals with a Z-score ⱖ 2 (Fig. 3B). Because the peptide was 9-aa in length, including 6 residues
N-terminal to the [Y/F] that are important for PTB-binding (39,
44), the spot array data suggests that the Nxx[Y/F] motif was
insufficient for high-affinity PTB-binding for the majority of
peptides examined or that a different region/motif in the corresponding proteins is involved in PTB-binding. To confirm
peptide-PTB binding in solution, we synthesized, individually,
12 of the 19 peptides after excluding the 7 peptides that are
localized in the extracellular region of the corresponding proteins. The peptides contained a fluorescein tag to facilitate
affinity measurement by the fluorescence polarization (FP)
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assay (38). The dissociation constants of the corresponding
dPTB-peptide interactions ranged from 0.5 M for a peptide
derived from ALK to 9.4 M for an ERBB2-derived peptide
(Table I). These values are comparable to those observed for
PTB interactions with the control peptides derived from NAK
and LNX1, two known Numb PTB-binding proteins (7, 25). It is
remarkable that the tyrosine kinase ALK contains three PTBbinding sites, strongly suggesting that Numb and ALK may
interact in vivo. It should be noted that for peptides that
showed strong binding in both the peptide spot array and
in-solution binding assay, the corresponding proteins all had
Z-scores greater than 3.0 on the ProtoArray (supplemental
Tables S2 and S3). Notwithstanding this observation, some
proteins with a Z ⬎ 3.0, such as C10orf91 and BMX (Fig. 2A),
do not harbor an Nxx[Y/F] motif, suggesting that these proteins may employ a different mechanism for PTB-binding.
Validation of Selected Numb-kinase Interactions—To validate findings from the ProtoArray screening and peptide binding assays, we carried out GST-pulldown or co-IP experiments to examine the interaction of Numb or Numb-PTB with
a selected group of RTKs. The presence of high-affinity binding sequences in ALK, ERBB2 and ROS1 suggest that these
kinases may bind to Numb via the PTB domain in vivo. Although Numb and ERBB2 were found to co-IP from the breast
cancer cell line SK-BR3 (Fig. 4A), both the dPTB and hPTB
domains were capable of pulling down ALK and ROS1 from
cells expressing these proteins in oncogenic fusion forms (Fig.
4B and 4C). Because not all tyrosine kinases that were positive on the ProtoArray contain the Nxx[Y/F] motif, we tested
the binding of a group of RTKs that do not harbor a recognizable motif. As shown in Fig. 4D– 4F, the tyrosine kinases
FGR, RET and FLT3 were capable of binding to the Numb
PTB domains despite the absence of the Nxx[Y/F] motif,
suggesting that additional motifs or modes of binding exist
for these proteins. The confirmation of Numb/PTB binding
to ALK, ERBB2, ROS1, FGR, RET, and FLT3 in cells, all of
which are oncogene products, suggests a role for Numb in
cancer pathogenesis via the regulation of oncogenic tyrosine kinases.
Genome-wide Prediction of Numb PTB-binding Proteins—
The human genome encodes ⬃20,000 proteins (45), ⬍50% of
which were represented in the protein microarray used in the
current study. Some proteins, membrane proteins that are not
readily amenable to expression and purification were under
represented in the Protoaray. Therefore, to identify Numbbinding proteins at the genome level, we must employ alternative strategies that complement the ProtoArray screening.
To this end, we developed a computational approach that
allows the prediction of Numb PTB-binding proteins in silico.
This approach took advantage of the ability of the Numb PTB
domain to recognize sequences containing the Nxx[Y/F] motif
and the computer program SMALI that was developed previ-
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FIG. 3. Verification of Numb-PTB interactions by peptide array and in-solution binding. A, Binding profile for the dNumb PTB domain
on an array of NxxF/Y motif-containing peptides. The peptides were derived from the PTB-interacting proteins identified using the ProtoArray
(Fig. 2). B, Distribution of Z scores for the positive binders on the peptide array in (A). C–K, Binding curves of selected peptides from the peptide
array for the dNumb PTB domain. See Table I for peptide sequences and Kd values.
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TABLE I
Binding affinities of peptides derived from several putative Numb-binding proteins identified in this study
UniProt Entry Name

Gene Name

Peptide Sequence

Kd (M)

SMALI Score

ProtoArray
ALK_HUMAN
ALK_HUMAN
ALK_HUMAN
EPHB2_HUMAN
ERBB2_HUMAN
M3K2_HUMAN
ROS1_HUMAN

ALK
ALK
ALK
EPHB2
ERBB2
MAP3K2
ROS1

CGNVNYGYQQQ
GGHVNMAFSQS
FPCGNVNYGYQ
ESFANAGFTSF
PAFDNLYYWDQ
SDYDNPIFEKF
SGVINESFEGE

1.6 ⫾ 0.15
0.7 ⫾ 0.04
0.5 ⫾ 0.02
8.3 ⫾ 1.2
9.4 ⫾ 0.3
9.1 ⫾ 0.8
0.7 ⫾ 0.02

1.247
1.1598
0.5257
1.2428
1.3717
1.3775
1.2859

SMALI prediction
JIP3_HUMAN
JIP4_HUMAN
PTN13_HUMAN
PLSI_HUMAN
DUSTY_HUMAN
SYT1_HUMAN
TULP4_HUMAN

MAPK8IP3
SPAG9, MAPK8IP4
PTPN13
PLS1
DSTYK, RIPK5
SYT1
TULP4

QGIVNKAFGIN
KGIENKAFDRN
GGYINASFIKI
NPKLNLAFVAN
DIFINQAFDMQ
NPYYNESFSFE
TDYVNSAFTED

1.5 ⫾ 0.04
1.7 ⫾ 0.04
2.4 ⫾ 0.49
5.3 ⫾ 0.33
7.7 ⫾ 0.50
8.5 ⫾ 0.35
8.5 ⫾ 0.7

1.565
1.5721
1.3359
1.497
1.7385
1.3876
1.7111

Control
LNX1_HUMAN
Q9U485_DROME

LNX1
NAK

PGLDNPAYVSS
TGFSNMSFEDF

2.5 ⫾ 0.2
1.1 ⫾ 0.08

1.2611
1.3358

FIG. 4. Numb or its PTB domain binds to tyrosine kinases
in cells. A, ERBB2 co-immunoprecipitated with Numb in SKBR3 cells. B–F, The Numb PTB domains pulled down ALK, ROS1,
FGR, RET and FLT3, respectively, from cells expressing these
proteins.
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ously for the identification of binding ligands for modular
interaction domains (36).
Because the Nxx[Y/F] core motif is insufficient to confer
high affinity binding (Fig. 2), we further defined the specificity
of the Numb PTB domain using the OPAL approach (35).
Specifically, we synthesized an OPAL membrane in which the
residues N⫺3 and [Y0/F0] were kept constant whereas the
other residues were systematically replaced by a naturally
occurring amino acid in the degenerated peptide library
xxNxxF/Yxx, where x represents a mixture of 19 natural amino
acids (except Cys). Probing the OPAL membrane by the dPTB
domain yielded a binding pattern that was indicative of its
specificity (Fig. 5A). Besides showing preference for a hydrophobic residue at the N-terminal region and proclivity for
charged amino acids at the C-terminal region to the Nxx[Y/F]
core motif, the PTB domain strongly selected for an Ala or Gly
at the ⫺1 position within the core motif. Inspection of dPTB in
complex with the NAK peptide (GFSNMSFEDFP) (38) reveals
that core motif (NMSF) adopts a ␤-turn structure with the
Ser⫺1 residue protruding into a small surface pocket on the
PTB domain (supplemental Fig. S6). These characteristics
explain why the small residues Ala and Gly are highly preferred for this position. Indeed, replacing the Ser⫺1 residue
with Ala led to ⬎850 fold increase in binding affinity for the
NAK peptide (39).
Based on the OPAL binding data, a scoring matrix that
reflects the residue preference for different positions of the
peptide was generated (supplemental Table S10). The scoring
matrix was subsequently imported into the computer program
SMALI (36) to predict candidate binding proteins for the Numb
PTB domain at the genome level. To identify high probability
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FIG. 5. Defining Numb PTB domain specificity by OPAL. A, Binding pattern of the dNumb PTB domain on an OPAL membrane with the
degenerate sequence xxNxx[F/Y]xx. B, A box plot showing the distribution of true binders (Table I) and non-binders (from Fig. 3A) relative to
the corresponding SMALI score. The medium value for true binders and non-binders are shown. C–I, Binding curves for representative peptides
with a SMALI score ⬎ 1.3. See Table I for peptide sequences and Kd values.

binders, we set the cut-off score in SMALI to 1.3 according to
the distribution pattern of validated binders (based on the Kd
value listed in Table I and supplemental Table S9) and nonbinders (based on Fig. 3A) (Fig. 5C). Using this cut-off, we
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identified 711 human proteins from the UniProt database (37)
(supplemental Table S11) that contain at least one high probability Numb PTB-binding sequence. Molecular function annotation (46) revealed that protein phosphatases, tyrosine
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phosphatases, were highly enriched in the SMALI-predicted
PTB interactome. Intriguingly, channel proteins and proteins
involved in vesicular transport were also enriched. To evaluate
the accuracy of the prediction, we selected representative
examples from the predicted binding peptides (with the
SMALI score ⬎1.3) and measured their affinities for the dPTB
domain by fluorescence polarization. Peptides representing
binding sequences for the phosphotyrosine phosphatases
PTP-13, the Ser/Thr kinase RIPK5, the JNK signaling scaffolds MAPK8IP3 (JIP3) and MAPK8IP4 (JIP4), and the membrane trafficking protein SYT1, the Tubby family transcription
factor TULP4, and the actin-binding protein PLS1 exhibited
high affinities for the Numb PTB domain with Kd values ranging from 1.5 to 8.5 M (Fig. 5C–5I and Table I). These data
indicate that specificity-based SMALI prediction can predict
binding partners with Kd values expected for interactions
mediated by a PTB domain or another modular interaction
domain (47, 48).
Functional Analysis of the Numb Interactome—Both the
TKs and STKs were enriched in the Numb-binding proteins
identified from the Protoarray (Fig. 2D–2E and supplemental
Fig. S7A). In contrast, protein phosphatases, especially tyrosine phosphatases, are enriched in proteins predicted to bind
the Numb PTB domain by SMALI (supplemental Fig. S7B). If
we combine data from both the ProtoArray screening and
SMALI prediction, then tyrosine kinases, serine/threonine kinases and tyrosine phosphatases are the most enriched protein categories in the resulting Numb interactome (Fig. 6A). It
is intriguing to note that the 42 TKs identified as Numbbinding proteins occupy essentially all branches of the human
kinome phylogeny tree (Fig. 6B). Our data strongly implicates
Numb in regulating the activity and/or function of tyrosine
kinases via direct binding to these proteins through its PTB
domain.
DISCUSSION

Mapping the PPI network in a systematic manner is key to
decoding the human proteome and deciphering the function
of individual proteins. In this regard, several high-throughput
approaches have been developed in the past decades for PPI
mapping at a large scale. These include mass spectrometry
(MS) based approaches such as TAP (tandem affinity purification) and BioID, luminescence-based interactome mapping,
and yeast two-hybrid (Y2H) screen (32, 33, 49). A limitation of
these approaches is that they cannot provide information
about the binding sites in most cases. To complement these
approaches, protein and peptide array-based assays have
been developed for systematic PPI identification in vitro. For
example, peptide and protein arrays have been used to identify PPI networks mediated by the Src homology 2 (SH2) and
3 (SH3) domains (50, 51). Recently, we have developed a
bidirectional protein-peptide array screening method to map
the PPI network mediated by the SH2 domains and immunoreceptor-tyrosine based regulatory motifs (52).
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In this study, we developed an integrated approach combining protein microarray, peptide spot array, OPAL screening
and bioinformatics analysis to identify binding partners for
modular interaction domains and applied this approach to
deciphering the Numb PTB domain interactome. We focused
on Numb because of its broad functions in animal development and disease pathogenesis (53). The IntAct (54) database
lists 30 Numb-interacting proteins (supplemental Table S12).
Although some of these interactions are direct and may involve the PTB domain, others may be indirect or involve other
regions of Numb. Furthermore, the Numb PTB domain could
bind a partner through peptide motifs that are either nonphosphorylated or phosphorylated (such Nxx[Y/F] (39) and
GPpY (43)) or through domain-domain interactions (55). It is
also highly likely that additional modes of ligand binding exist
for the Numb PTB domain. The multiple modes of ligand
binding by the Numb PTB domain provides a rationale for the
generally low re-identification rate of known binding partners
from either the ProtoArray screening or SMALI prediction. Of
the 11 known binding partners of Numb that were included in
the Protoarray, four were identified in our screen (supplemental Table S12). The 7 Numb-binding proteins that were missed
in our protein array screen may not bind directly to Numb or
its PTB domain. The SMALI prediction captured four known
Numb-binding proteins (supplemental Table S12), reflecting
again that many Numb-protein interactions do not necessarily
involve the PTB domain or are mediated by the Nxx[Y/F] motif.
Nevertheless, combining ProtoArray screening and specificity-based prediction, we identified an unprecedented ⬃900
proteins that could potentially interact with Numb. That the
Numb PTB domain is capable of putatively binding to such a
large number of proteins is mind-boggling. Although stringent
cut-off values (i.e. Z-score ⬎2 or SMALI score ⬎1.3) were
applied in the identification of binding partners, it is inevitable
that false positives have been included in the resulting interactome. The use of the dNumb PTB domain as the probe for
array screening might have contributed to false positives. The
dNumb PTB domain is more stable than its mammalian counterparts (38, 39) and appears to bind more strongly than the
latter to the full-length proteins tested (Fig. 3). On the other
hand, the large number of binding partners may reflect the
promiscuity of the PTB domain, and likely, modular domains
in general. Along this line, the human genome encodes only a
few dozens of PTB domains (20), yet thousands of proteins
containing the Nxx[Y/F] motif. Therefore a given PTB domain
has the potential to interact with hundreds or even more
proteins containing the motif. Similarly, the identified phosphotyrosine sites far outnumber the SH2 domains encoded by
the human genome, and PxxP motif-containing proteins far
outnumber the SH3 domains. Therefore, it is likely that these
modular domains might sample through multiple potential
binding partners in the cell before a productive interaction
could occur. Notwithstanding the intrinsic promiscuity of the
modular domains, the specificity of modular domain-medi-
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FIG. 6. The Numb interactome is enriched for proteins involved in phosphorylation signaling. A, Molecular function enrichment for the
Numb-binding proteins identified in this study. B, Distribution of Numb-binding TKs in the human kinome phylogeny tree. Fig. reproduced
courtesy of Cell Signaling Technology, Inc.

ated protein-protein interactions in the cell may be regulated
by protein expression, modification, and subcellular localization, by additional regions in the interacting pairs or by other
proteins that may function as scaffolds (47).
Although further investigations are warranted to define the
physiological relevance of the vast number of interactions
identified in the present study, it is tempting to speculate the
functions of Numb based on the expansive network of puta-
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tive binding partners. Of the proteins identified from both the
ProtoArray screening and SMALI prediction, protein kinases
and phosphatases, especially tyrosine kinases and phosphotyrosine phosphatases, are most abundantly represented (Fig.
6A). It is rather intriguing that ⬃50% of all TKs are capable of
binding to the Numb PTB domain (Fig. 6B), some of which
contain high affinity binding motifs and/or are confirmed for
binding in cells (Fig. 3). This suggests that Numb may play a
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general role in regulating protein phosphorylation and kinase
signaling through direct interactions with multiple kinases and
phosphatases. Prior to this study, Numb has been shown to
interact with three RTKs, namely EphB2, TrkB and EGFR. The
Numb-EphB2 interaction plays a role in ephrin-B1-induced
spine development and maturation (56). The Numb-TrkB interaction alters TrkB’s chemotactic response to BDNF (brainderived neurotrophic factor) ligand (17). It has been shown
that Numb binding decreases EGFR protein level to regulate
the fate of glioblastoma stem-like cells (57). However, little direct
evidence has been provided in these studies to make the conclusion that Numb directly interact with these RTKs. Here, we
show that RTKs are highly enriched in the Numb interactome;
and oncogenic RTKs such as ALK and ErbB2 can directly
interact with Numb in the cell. Given the established function of
Numb in endocytosis, it is likely that Numb may regulate the
endocytosis or trafficking of these RTKs and other membrane
proteins. In this regard, Numb may play a role as a critical
regulator of trans-membrane signal transduction by altering
membrane receptor abundance, particularly in the context of
growth factor stimulated RTK signaling. Further experiments are
also needed to investigate if Numb is involved in the endocytosis or intracellular trafficking of PTPs, thereby adding an extra
layer of regulation to phosphotyrosine signaling dynamics.
Besides TK and PTPs, transcription factors such as TULP4
have also been identified in the putative Numb interactome.
We reported previously that Numb binds to the transcriptional
factor p53 through its PTB domain and the Numb-p53 interaction regulates p53 stability and the transcription of several
genes involved in DNA damage response or apoptosis (58).
Nevertheless, very few nuclear binding partners have been
identified for Numb to date, even though Numb can localize to
the nucleus (29, 40, 59). It is also not fully understood how
Numb alters transcription activity at a molecular level. Given
the potential for Numb to interact with a wide array of different
proteins, it is possible that Numb may regulate gene transcription by directly binding to transcriptional factors.
In conclusion, we have identified the largest putative Numb
interactome reported to date, revealing a general role for
Numb in protein kinase signaling. Because of the pivotal role
of protein kinases in tumorigenesis, our work suggests that
Numb is a potential therapeutic target for cancers driven by
aberrant kinase activation. Future studies focusing on elucidating the physiological relevance of the putative Numb interactome will undoubtedly shed new light on how Numb
regulates different cellular processes under normal or pathological conditions.
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